Thursday 16 October, 2025
Introduction: Population-based pharmacokinetic modeling (popPK) consists of estimating and quantifying the different sources of variability that can influence the behavior…
Read moreAbstracts
External evaluation of population pharmacokinetic models of gentamicin in critically ill patients
Thursday 16 October, 2025
Introduction and Objectives: In a context of anti-infective drug overuse and resistance, their proper use and the prevention of resistant…
Read moreCapped dosing of desmopressin in Von Willebrand disease: Quantification of the relationship between desmopressin plasma concentration and Von Willebrand factor activity
Thursday 16 October, 2025
Introduction: Von Willebrand disease (VWD) is the most common inherited bleeding disorder and is caused by a deficiency or qualitative…
Read morePhysiologically-based pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant FIX (rFIX) to characterize extravasation and binding to type IV collagen
Thursday 16 October, 2025
Introduction: Hemophilia B (HB) is caused by a deficiency of coagulation factor IX (FIX), which results in bleeding, typically in joints…
Read morePopulation pharmacokinetic analysis to investigate the effect of ethnicity for extrapolating data from Caucasians to Koreans in eslicarbazepine acetate therapy
Thursday 16 October, 2025
Objectives: Eslicarbazepine acetate (ESL) is an antiseizure medicationfor monotherapy or adjunctive therapy for focal seizures. ESL is extensively hydrolyzed primarily…
Read moreThe effect of CYP2D6 phenotypes on the pharmacokinetics of propafenone: a systematic review and meta-analysis
Thursday 16 October, 2025
Objectives: Propafenone (PPF) is a class 1C antiarrhythmic agent mainly metabolized to 5-hydroxypropafenone by cytochrome (CYP) 2D6 and norpropafenone by…
Read moreSemi-mechanistic PK modelling of drug-macrophage interactions affecting the disposition of liposomal amphotericin B in plasma and skin tissue of post kala-azar dermal leishmaniasis patients
Thursday 16 October, 2025
Objectives: Leishmaniasis is a neglected parasitic tropical disease, clinically characterized by a large production of macrophages in which Leishmania parasites…
Read moreElucidating the effect of platelet binding on vincristine distribution by a physiologically based pharmacokinetic (PBPK) approach
Thursday 16 October, 2025
Objectives: A poor correlation between vincristine dose and plasma exposure has been observed, indicating nonlinear drug pharmacokinetics (PK) [1]. Several…
Read moreDisease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in Eastern Africa
Thursday 16 October, 2025
Objectives: Post-kala-azar dermal leishmaniasis (PKDL) is a skin complication following a primary visceral leishmaniasis (VL) infection. Treatment and dosing regimens for…
Read moreOptimizing dosing strategies for post-kala-azar dermal leishmaniasis: a geographical comparison of systemic and skin pharmacokinetics and pharmacodynamics of antileishmanial drugs
Thursday 16 October, 2025
Objectives: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatological complication that arises after the successful treatment of the neglected tropical disease…
Read more